Boehringer Ingelheim Corporation and Priaxon Announce a Collaboration to Research and Develop Novel Treatments for Cancer
1/19/2010 10:39:52 AM
MUNICH & INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and Priaxon entered into a worldwide collaboration to research and develop mdm2/p53 inhibitors for the treatment of cancer. Priaxon is providing its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigate inhibition of protein-protein interactions. p53 is a human tumor suppressor protein. It has been shown that in tumors with wild-type p53, the restoration of p53 tumor-suppressive functions can be achieved by blocking a cellular interaction of mdm21 and p53. This may reactivate the “genome guardian” function of p53 and is therefore an interesting approach for treating various oncological indications.
comments powered by